Combined VEGFR and MAPK pathway inhibition in angiosarcoma.

Although it did not reach statistical significance, phosphorylated ERK trended towards an increase in cediranib treated cells, and this was suppressed with the addition of trametinib (Fig. 4 A).

also in 111,027 other papers